How to Assess Response to Inclisiran
Measure LDL-C levels as early as 30 days after the initial injection, with the primary assessment at day 510 (approximately 17 months) or when clinically indicated. 1
Timing of LDL-C Measurement
- The FDA label specifies that LDL-C lowering effects may be measured as early as 30 days after initiation, allowing for early assessment of treatment response 1
- Maximum LDL-C reduction occurs at day 510 (after the complete dosing sequence of day 1, day 90, day 270, and day 450), with mean placebo-corrected reductions of 50.7% demonstrated in pooled phase 3 trials 2
- LDL-C reductions become apparent within 14 days post-dose, with mean reductions of 38-51% observed between 30 to 180 days after a single dose 1
Target LDL-C Goals for Response Assessment
- For patients with atherosclerotic cardiovascular disease (ASCVD), assess whether LDL-C is <55 mg/dL with ≥50% reduction from baseline 3
- In the VICTORION-Initiate study, 81.8% of patients achieved LDL-C <70 mg/dL with inclisiran versus 22.2% with usual care, and 71.6% achieved <55 mg/dL versus 8.9% with usual care 4
- If LDL-C remains ≥100 mg/dL (or non-HDL-C ≥130 mg/dL) despite inclisiran therapy, referral to a lipid specialist is recommended 5
Additional Lipid Parameters to Monitor
- Assess total cholesterol, apolipoprotein B (apo B), and non-HDL-C levels, which are all significantly reduced with inclisiran therapy 1, 2
- Mean reductions in total cholesterol of approximately 31% and apo B levels of approximately 41% can be expected 6
- PCSK9 levels are reduced by approximately 75-79% at day 120 and maintained throughout treatment, though this is not routinely measured in clinical practice 1, 6
Monitoring Schedule
- Initial assessment: 30 days after first injection to confirm early response 1
- Follow-up assessment: Day 90 (before second dose) to evaluate initial efficacy 1
- Primary efficacy assessment: Day 510 (approximately 17 months) after completing the full dosing sequence 2
- Ongoing monitoring: Every 6 months when clinically indicated, aligned with the maintenance dosing schedule 7
Safety Monitoring
- Monitor for injection-site reactions, which occur in approximately 5% of patients but are predominantly mild and non-persistent 2
- Liver function tests, kidney function tests, creatine kinase, and platelet counts do not require routine monitoring as these parameters do not differ between inclisiran and placebo groups 2
- The safety profile is favorable and similar to placebo, with serious adverse events occurring at comparable rates 4, 6
Inadequate Response Criteria
- If LDL-C reduction is <50% from baseline or LDL-C remains ≥100 mg/dL (or non-HDL-C ≥130 mg/dL) on maximally tolerated statin therapy with ezetimibe and inclisiran, refer to a lipid specialist 5
- Consider that severe hypertriglyceridemia may interfere with LDL-C measurement accuracy and should be addressed with aggressive triglyceride-lowering therapy before assessing inclisiran response 7
- Inclisiran has no effect on triglycerides, so its efficacy should be judged solely on LDL-C reduction 7
Long-Term Efficacy Assessment
- Sustained LDL-C reductions of approximately 50% are maintained with twice-yearly dosing, as demonstrated through day 540 in clinical trials 8, 2
- The ORION-3 extension study showed LDL-C reductions of 44.2% maintained through 4 years of treatment, confirming long-term durability 3
- Continue monitoring adherence to the twice-yearly dosing schedule, as this is critical for maintaining therapeutic effect 7